Work

Myeloid Maturity: ATRA to Enhance Anti–PD-1?

Year: 2023

Type: editorial

Abstract: Myeloid-derived suppressor cells (MDSC) are associated with resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may induce maturation of MDSCs and alter their immunosuppressive effects. Adding ATRA to pembrolizumab may target this resistance mechanism to enhance the overall impact of anti-PD-1-based immunotherapy. See related article by Tobin et al., p. 1209.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-22-3652

Authors: Daniel J. Olson, Jason J. Luke

Institutions: University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Astellas Pharma, National Institutes of Health, National Cancer Institute, National Institute of Dental and Craniofacial Research